Table 3.

Participant characteristics at baseline enrollment for activation study

		HIV-infected (n = 11)	HIV-uninfected (n = 6)
Age, yr	Median	33	37
	Range	24–63	26–47
Ethnicity	Xhosa	11 (100)	6 (100)
Sex	Male	3 (27.3)	2 (33.3)
	Female	8 (72.7)	4 (66.7)
Current smoking	Yes	2 (18.2)	0 (0)
	No	9 (81.8)	6 (100)
Regular alcohol*	Yes	1 (9.1)	1 (16.7)
	No	10 (90.9)	5 (83.3)
BCG	Yes	2 (18.2)	4 (66.7)
	No	6 (54.5)	0 (25)
	Unsure/unclear	3 (27.3)	2 (33.3)
Comorbidity†	Yes	6 (54.5)	2 (33.3)
	No	5 (45.5)	4 (66.7)
Cotrimoxazole prophylaxis	Yes	9 (81.8)	N/A
	No	2 (18.2)
Vitamin treatment	Vitamin B Co-Strong	8 (72.7)	N/A
	Vitamin C	5 (45.5)
Other medication in previous 3 mo‡	Yes	6 (54.5)	2 (33.3)
	No	5 (45.5)	4 (66.7)
CD4 count, ×106/L (n = 10)	Median	170	N/A
	Range	55–371
Log [HIV viral load (copies/ml)]	Median	5.14	N/A
	Range	3.96–5.96

Definition of abbreviations: BCG = Mycobacterium bovis–Bacille Calmette–Guerin; N/A = not applicable.

Data presented as n (%) unless otherwise noted.

^*Defined as at least once per week.

^†Identified comorbidities: epilepsy, oral candidiasis, recent finger infection, eczema, tinea cutis, shingles, chronic cough.

^‡Identified medications: phenytoin, nystatin, ibuprofen, paracetamol, folic acid, acyclovir, antifungal creams, steroid creams.